The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The study evaluated registry data from a heavily pretreated cohort to assess the CAR T-cell therapy’s performance outside of clinical trials. The findings demonstrated high overall response rates and safety profiles consistent with the pivotal TRANSCEND trial.
In this session from the SOHO Insider Community Oncology series, Shakira J. Grant, MBBS, MSCR, founder and CEO of CROSS Global Research and Strategy, discusses how artificial intelligence is shaping pathology workflows and clinical treatment decisions in hematology and oncology.
As part of the SOHO Ambassador Program, the meeting drew approximately two hundred people from across the region and featured top clinicians from France and the United States.
Parameters for increasing life-years saved including sustained research investment across the public and private sectors and faster development of first-in-class drugs, specifically noting acute myeloid leukemia and other myeloid cancers, according to a press release published by Blood Cancer United.
In this episode of the SOHO Insider podcast, host Marin Xavier, MD, hematologist and oncologist at Scripps Clinic in San Diego, and Krish Patel, MD, executive director of Hematologic Cancer Research at Sarah Cannon Research Institute, discuss frontline and relapsed management strategies in mantle cell lymphoma.
In this video with SOHO Insider, Syrine Bel Haj Yahia, a SOHO France Young Investigator, discusses her research.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
